MNPR Monopar Therapeutics
Pharmaceutical Preparations · Nasdaq · SEC CIK 1645469 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-15.3%
ROA-15.0%
ROIC (approx.)-45.6%
Asset turnover—
Leverage & solvency
Liabilities / assets2.4%
Debt / equity0.00x
Current ratio43.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $9.90M | $13.01M |
| SG&A expense | $6.80M | $3.16M |
| Operating income | -$16.70M | -$16.16M |
| Pretax income | -$13.72M | -$15.59M |
| Income tax | $800 | $800 |
| Net income | -$13.72M | -$15.59M |
| EPS (basic) | -1.85 | -4.11 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $61.83M | $45.82M |
| Short-term investments | $60.88M | $45.53M |
| Current assets | $140.46M | $60.29M |
| Total assets | $140.72M | $60.29M |
| Current liabilities | $2.74M | $5.25M |
| Total liabilities | $2.89M | $5.25M |
| Shareholders' equity | $137.83M | $55.04M |
| Shares outstanding | 6.69M | 6.10M |
| Cash flow statement | ||
| Operating cash flow | -$12.20M | -$6.40M |
| Investing cash flow | -$63.45M | -$14.34M |
| Financing cash flow | $91.57M | $59.29M |
| Stock-based compensation | $4.84M | $1.14M |
| Share buybacks | $35.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.